Sino Biopharmaceutical Limited

1177

KYG8167W1380

Sino Biopharmaceutical Limited specialises in the development, manufacture and marketing of biopharmaceutical products primarily for the treatment of cancer, ophthalmia, hepatitis, orthopedic diseases and respiratory disorders. Net sales break down by category of products as follows: - chemical medicine products and biopharmaceutical drugs (97.6%); - other (2.4%).

Sector

Pharmaceuticals

Calendar

29/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

HONG KONG HANG SENG

More about the company

Income Statement Evolution

More financial data

Ratings for Sino Biopharmaceutical Limited

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.524 CNY

Average target price

4.257 CNY

Spread / Average Target

+68.67%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SINO BIOPHARMACEUTICAL LIMITED	-21.04%	6.39B
ELI LILLY AND COMPANY	+48.22%	780B
NOVO NORDISK A/S	+41.76%	627B
MERCK & CO., INC.	+20.03%	334B
ABBVIE INC.	+7.07%	296B
ASTRAZENECA PLC	+17.60%	244B
ROCHE HOLDING AG	-0.41%	217B
NOVARTIS AG	+11.54%	214B
AMGEN INC.	+4.37%	161B
PFIZER, INC.	-3.25%	159B

Other Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 01:38:23 12/06/2024 pm IST			5-day change	1st Jan Change
2.74 ^HKD	+0.74%		-3.52%	-21.04%

11:56am	Sino Biopharmaceutical Gets Marketing Go-Ahead for MRI Contrast Agent from Chinese Regulator	MT
10:35am	Sino Biopharmaceutical Limited Announces Approval for Marketing of Gadoteridol Injection	CI

Sino Biopharmaceutical Gets Marketing Go-Ahead for MRI Contrast Agent from Chinese Regulator	03:26pm	MT
Sino Biopharmaceutical Limited Announces Approval for Marketing of Gadoteridol Injection	02:05pm	CI
Sino Biopharmaceutical's Phase 2 Trial Results of Lung Cancer Tablet Published in Medical Journal	11/06	MT
Sino Biopharmaceutical Limited Announces Publication of Study Findings of Phase II Clinical Trial of KRAS G12C Inhibitor "Garsorasib (D-1553) in the Lancet Respiratory Medicine	11/06	CI
Sino Biopharmaceutical Limited Announces KRAS G12C Inhibitor Garsorasib Tablet (D-1553) Included in the Breakthrough Therapeutic Designation Process	11/06	CI
Chinese drugmakers developing generic drugs of Novo Nordisk's Ozempic	06/06	RE
Sino Biopharmaceutical Presents Findings of Anti-Tumor Drug at American Cancer Conference	05/06	MT
Sino Biopharmaceutical Cuts Conversion Price of Euro-Denominated Bonds Due 2025	05/06	MT
Sino Biopharmaceutical Limited Announces Retirement of Ms. Li Mingqin as Executive Director	05/06	CI
Sino Biopharmaceutical's Renal Cancer Combination Treatment Shows Promise in Phase III Trials	24/05	MT
Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsules for First-Line Treatment of Advanced Renal Cell Carcinoma	23/05	CI
Sino Biopharmaceutical's Novel Lung Cancer Drug Approved in China; Shares Up 5%	09/05	MT
Sino Biopharmaceutical Limited Receives Marketing Approval from National Medical Products Administration of China	09/05	CI
Wall Street, Earnings, Federal Reserve Roil Asian Stock Markets	30/04	MT
Sino Biopharmaceutical Limited Announces Approval for Marketing of Category 1 Unecritinib Fumarate Capsules	30/04	CI
Sino Biopharm Completes Phase I Study of Hepatitis B Drug	25/04	MT
Lull in Geopolitical Tensions Lifts Asian Stock Markets	22/04	MT
Hong Kong shares jump on policy support; China slips	22/04	RE
Hong Kong shares jump 1.5% on policy support; China slips	22/04	RE
Sino Biopharmaceutical Reaches Primary Endpoint for Clinical Research of Myelofibrosis Drug	19/04	MT
Sino Biopharmaceutical Limited Announces Category 1 Innovative Drug Rovadicitinib Obtained Positive Results in Key Clinical Research for Registration	18/04	CI
Sino Biopharm EBT Buys Back HK$12 Million Worth of Shares	17/04	MT
Sino Biopharmaceutical Presents Cancer Drug's Phase-II Clinical Trial Results at AACR 2024	11/04	MT
Sino Biopharmaceutical Trustee Repurchases Shares	08/04	MT
Sino Biopharmaceutical to Develop Boehringer Ingelheim's Cancer Treatments in China	08/04	MT